Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia

Current Pharmaceutical Design

Volumn 20, Issue 31, 2014, Pages 5077-5092

  Boggs, Douglas L ^a,b   Carlson, Jon ^a,b   Cortes Briones, Jose ^a,b   Krystal, John H ^a,b   D'Souza, D Cyril ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognition; nAChR; Nicotine; Schizophrenia

Indexed keywords

BRADANICLINE; BUNGAROTOXIN RECEPTOR; DONEPEZIL; GALANTAMINE; NICOTINE; NICOTINE GUM; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NOOTROPIC AGENT; RIVASTIGMINE; TROPISETRON; VARENICLINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR;

ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; IN VIVO STUDY; INFORMATION PROCESSING; LATENT PERIOD; MINI MENTAL STATE EXAMINATION; MISMATCH NEGATIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SENSORY GATING; SMOKING; SMOKING CESSATION; ATTENTION DEFICIT DISORDER; DRUG TARGETING; EXPERIMENTAL COGNITIVE TEST; NONHUMAN; RECEPTOR AFFINITY; BRAIN; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; EVOKED RESPONSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SELF MEDICATION;

BRAIN; COGNITION DISORDERS; EVOKED POTENTIALS; HUMANS; NICOTINE; NICOTINIC AGONISTS; NOOTROPIC AGENTS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF MEDICATION; SMOKING;

EID: 84906278089     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666131216121019     Document Type: Article

References (234)

1. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: e12.
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998; 12: 426-45.
3. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med 2011; 41: 225-41.
4. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 2004; 72: 21-8.
5. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry 2005; 57: 688-91.
6. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 2000; 26: 119-36.
7. Tsang HW, Leung AY, Chung RC, Bell M, Cheung WM. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry 2010; 44: 495-504.
8. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsycho-pharmacol Biol Psychiatry 2003; 27: 1081-90.
9. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007; 33: 1120-30.
10. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633-47.
11. Bradley SR, Lameh J, Ohrmund L, et al. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 2010; 58: 365-73.
12. O'Donnell CJ, Rogers BN, Bronk BS, et al. Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. J Med Chem 2010; 53: 1222-37.
13. Radek RJ, Kohlhaas KL, Rueter LE, Mohler EG. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists. Curr Pharm Des 2010; 16: 309-22.
14. Homayoun H, Moghaddam B. Group 5 metabotropic glutamate receptors: role in modulating cortical activity and relevance to cognition. Eur J Pharmacol 2010; 639: 33-9.
15. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994; 116: 143-51.
16. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155: 1490-501.
17. Hughes J, Hatsukami D, Mitchell J, Dahlgren L. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-997.
18. Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23: 247-54.
19. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76: 135-57.
20. de Leon J, Becona E, Gurpegui M, Gonzalez-Pinto A, Diaz FJ. The association between high nicotine dependence and severe mental illness may be consistent across countries. J Clin Psychiatry 2002; 63: 812-6.
21. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998; 33: 113-8.
22. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neuroscience & Biobehavioral Reviews 2005; 29: 1021-1034.
23. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol 2000; 61: 75-111.
24. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002; 53: 606-17.
25. Chavez-Noriega LE, Crona JH, Washburn MS, Urrutia A, Elliott KJ, Johnson EC. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes. J Pharmacol Exp Ther 1997; 280: 346-56.
26. Rueter LE, Donnelly-Roberts DL, Curzon P, Briggs CA, Anderson DJ, Bitner RS. A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor. CNS Drug Rev 2006; 12: 100-12.
27. Fabian-Fine R, Skehel P, Errington ML, et al. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 2001; 21: 7993-8003.
28. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73-120.
29. Cosgrove KP, Batis J, Bois F, et al. beta2-Nicotinic acetylcholine receptor availability during acute and prolonged abstinence from tobacco smoking. Arch Gen Psychiatry 2009; 66: 666-76.
30. Breese CR, Marks MJ, Logel J, et al. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997; 282: 7-13.
31. Yu KD, Liu Q, Wu J, Lukas RJ. Kinetics of desensitization and recovery from desensitization for human alpha4beta2-nicotinic acetylcholine receptors stably expressed in SH-EP1 cells. Acta Pharmacol Sin 2009; 30: 805-17.
32. Mineur YS, Picciotto MR. Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochem Pharmacol 2008; 75: 323-33.
33. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004; 306: 1029-32.
34. Lendvai B, Kassai F, Szajli A, Nemethy Z. alpha7 Nicotinic acetylcholine receptors and their role in cognition. Brain Res Bull 2012.
35. Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007; 78: 225-46.
36. Jensen AA, Frolund B, Liljefors T, Krogsgaard-Larsen P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem 2005; 48: 4705-45.
37. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-33.
38. Leonard S, Gault J, Adams C, et al. Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci 1998; 12: 195-201.
39. Court J, Spurden D, Lloyd S, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999; 73: 1590-7.
40. Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999; 10: 1779-82.
41. Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000; 23: 351-64.
42. Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience 2000; 98: 79-87.
43. Durany N, Zochling R, Boissl KW, et al. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000; 287: 109-12.
44. Leonard S, Adler LE, Benhammou K, et al. Smoking and mental illness. Pharmacol Biochem Behav 2001; 70: 561-70.
45. Marutle A, Zhang X, Court J, et al. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 2001; 22: 115-26.
46. Martin-Ruiz CM, Haroutunian VH, Long P, et al. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 2003; 54: 1222-33.
47. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr Scand 2006; 114: 211-5.
48. Mathew SV, Law AJ, Lipska BK, et al. Alpha7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Hum Mol Genet 2007; 16: 2921-32.
49. Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S. Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 2010; 40: 185-95.
50. Thomsen MS, Weyn A, Mikkelsen JD. Hippocampal alpha7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disord 2011; 13: 701-7.
51. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004; 70: 315-29.
52. D'Souza DC, Esterlis I, Carbuto M, et al. Lower Beta2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am J Psychiatry 2012; 169: 326-34.
53. Brasic JR, Cascella N, Kumar A, et al. Positron emission tomography experience with 2-[(1)(8)F]fluoro-3-(2(S)-azetidinyl-methoxy)pyridine (2-[(1)(8)F]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse 2012; 66: 352-68.
54. Kraguljac NV, Reid M, White D, et al. Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res 2012; 203: 111-25.
55. Dickinson D, Harvey PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 2009; 35: 403-14.
56. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005; 31: 5-19.
57. Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 2011; 125: 161-8.
58. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007; 64: 532-42.
59. Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, Jeste DV. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol Psychiatry 2003; 53: 422-30.
60. Hahn B, Robinson BM, Harvey AN, et al. Visuospatial attention in schizophrenia: deficits in broad monitoring. J Abnorm Psychol 2012; 121: 119-28.
61. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci 1994; 6: 348-57.
62. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004; 72: 29-39.
63. Gray BE, McMahon RP, Gold JM. General intellectual ability does not explain the general deficit in schizophrenia. Schizophr Res 2013; 147: 315-9.
64. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 2006; 32 Suppl 1: S44-63.
65. Gold JM, Queern C, Iannone VN, Buchanan RW. Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity. Am J Psychiatry 1999; 156: 1944-50.
66. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004; 68: 283-97.
67. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201-22.
68. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008; 165: 203-13.
69. Kern RS, Nuechterlein KH, Green MF, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry 2008; 165: 214-20.
70. Green MF, Nuechterlein KH. The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 2004; 72: 1-3.
71. Green MF, Nuechterlein KH, Gold JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 2004; 56: 301-7.
72. Baker EL, Letz R, Fidler A. A computer-administered neuro-behavioral evaluation system for occupational and environmental epidemiology. Rationale, methodology, and pilot study results. J Occup Med 1985; 27: 206-12.
73. O'Halloran JP, Kemp AS, Gooch KN, et al. Psychometric comparison of computerized and standard administration of the neurocognitive assessment instruments selected by the CATIE and MATRICS consortia among patients with schizophrenia. Schizophr Res 2008; 106: 33-41.
74. Kline P. A handbook of test construction: Introduction to psychometric design. Methuen 1986.
75. Keefe RS, Harvey PD, Goldberg TE, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res 2008; 102: 108-15.
76. Hill SK, Sweeney JA, Hamer RM, et al. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. J Int Neuropsychol Soc 2008; 14: 209-21.
77. Paul RH, Lawrence J, Williams LM, Richard CC, Cooper N, Gordon E. Preliminary validity of integneuro: a new computerized battery of neurocognitive tests. Int J Neurosci 2005; 115: 1549-67.
78. Pietrzak RH, Olver J, Norman T, Piskulic D, Maruff P, Snyder PJ. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. J Clin Exp Neuropsychol 2009; 31: 848-59.
79. Pantelis C, Barnes TR, Nelson HE, et al. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997; 120 (Pt 10): 1823-43.
80. Rugg MD, Coles MG. Electrophysiology of mind: Event-related brain potentials and cognition. Oxford University Press 1995.
81. Boutros NN, Belger A, Campbell D, D'Souza C, Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res 1999; 88: 119-30.
82. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 1982; 17: 639-54.
83. Patterson JV, Hetrick WP, Boutros NN, et al. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res 2008; 158: 226-47.
84. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry 2008; 64: 376-84.
85. Naatanen R, Gaillard AW, Mantysalo S. Early selective-attention effect on evoked potential reinterpreted. Acta Psychol (Amst) 1978; 42: 313-29.
86. Naatanen R, Alho K. Mismatch negativity--a unique measure of sensory processing in audition. Int J Neurosci 1995; 80: 317-37.
87. Naatanen R, Pakarinen S, Rinne T, Takegata R. The mismatch negativity (MMN): towards the optimal paradigm. Clin Neurophysiol 2004; 115: 140-4.
88. Näätänen R, Kähkönen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: A review. International Journal of Neuropsychopharmacology 2009; 12: 125-135.
89. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005; 76: 1-23.
90. Umbricht D, Javitt D, Novak G, et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998; 44: 716-25.
91. Umbricht D, Javitt D, Novak G, et al. Effects of risperidone on auditory event-related potentials in schizophrenia. Int J Neuropsychopharmacol 1999; 2: 299-304.
92. Kasai K, Yamada H, Kamio S, et al. Do high or low doses of anxiolytics and hypnotics affect mismatch negativity in schizophrenic subjects? An EEG and MEG study. Clin Neurophysiol 2002; 113: 141-50.
93. Catts SV, Shelley AM, Ward PB, et al. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. American Journal of Psychiatry 1995; 152: 213-219.
94. Umbricht D, Koller R, Schmid L, et al. How specific are deficits in mismatch negativity generation to schizophrenia? Biological Psychiatry 2003; 53: 1120-1131.
95. Fisher DJ, Labelle A, Knott VJ. Auditory hallucinations and the mismatch negativity: Processing speech and non-speech sounds in schizophrenia. International Journal of Psychophysiology 2008; 70: 3-15.
96. Dulude L, Labelle A, Knott VJ. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J Clin Psychopharmacol 2010; 30: 541-8.
97. Horton J, Millar A, Labelle A, Knott VJ. MMN responsivity to manipulations of frequency and duration deviants in chronic, clozapine-treated schizophrenia patients. Schizophrenia Research 2011; 126: 202-211.
98. Rasser PE, Schall U, Todd J, et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophrenia Bulletin 2011; 37: 131-140.
99. Michie PT. What has MMN revealed about the auditory system in schizophrenia? Int J Psychophysiol 2001; 42: 177-94.
100. Javitt DC, Doneshka P, Grochowski S, Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch Gen Psychiatry 1995; 52: 550-8.
101. Javitt DC, Grochowski S, Shelley AM, Ritter W. Impaired mismatch negativity (MMN) generation in schizophrenia as a function of stimulus deviance, probability, and interstimulus/ interdeviant interval. Electroencephalogr Clin Neurophysiol 1998; 108: 143-53.
102. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Naatanen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biol Psychiatry 2008; 63: 58-64.
103. Fisher DJ, Labelle A, Knott VJ. The right profile: mismatch negativity in schizophrenia with and without auditory hallucinations as measured by a multi-feature paradigm. Clin Neurophysiol 2008; 119: 909-21.
104. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Näätänen R. Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. Biological psychiatry 2008; 63: 58-64.
105. Polich J. Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol 2007; 118: 2128-48.
106. Polich J, Criado JR. Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol 2006; 60: 172-85.
107. Polich J. Theoretical overview of P3a and P3b. In: Detection of Change: Event-related potential and IMRI findings. Ed, Polich, J 2003: 83-98.
108. Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 2003; 40: 684-701.
109. Heishma SJ, Taylor RC, Henningfield JE. Nicotine and smoking: A review of effects on human performance. Experimental and Clinical Psychopharmacology 1994; 2: 345.
110. Heishman SJ, Kleykamp BA, Singleton EG. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology 2010; 210: 453-469.
111. Wallace TL, Bertrand D. Alpha7 neuronal nicotinic receptors as a drug target in schizophrenia. Expert Opin Ther Targets 2013; 17: 139-55.
112. D'Souza MS, Markou A. Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 2012; 62: 1564-1573.
113. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2004; 29: 1378.
114. Larrison-Faucher AL, Matorin AA, Sereno AB. Nicotine reduces antisaccade errors in task impaired schizophrenic subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004; 28: 505-516.
115. Tanabe J, Tregellas JR, Martin LF, Freedman R. Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biological psychiatry 2006; 59: 754-761.
116. Dulude L, Labelle A, Knott VJ. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. Journal of clinical psychopharmacology 2010; 30: 541.
117. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996; 15: 429-436.
118. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia bulletin 1998; 24: 189-202.
119. Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 1999; 21: 195-202.
120. Dépatie L, O'Driscoll GA, Holahan ALV, et al. Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002; 27: 1056-1070.
121. Inami R, Kirino E, Inoue R, Suzuki T, Arai H. Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients. Neuropsychobiology 2007; 56: 64-72.
122. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2007; 33: 480-490.
123. Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, Evins AE. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology 2008; 199: 89-98.
124. Hong LE, Schroeder M, Ross TJ, et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophrenia bulletin 2011; 37: 416-425.
125. Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 2004; 55: 850-8.
126. Sherr JD, Myers C, Avila MT, Elliott A, Blaxton TA, Thaker GK. The effects of nicotine on specific eye tracking measures in schizophrenia. Biological psychiatry 2002; 52: 721-728.
127. Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsycho-pharmacology 2002; 27: 479-497.
128. Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharma-cology 2004; 174: 334-340.
129. Smith RC, Warner-Cohen J, Matute M, et al. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsycho-pharmacology 2005; 31: 637-643.
130. Olincy A, Johnson LL, Ross RG. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry research 2003; 117: 223-236.
131. Hahn B, Harvey AN, Concheiro-Guisan M, Huestis MA, Holcomb HH, Gold JM. A Test of the Cognitive Self-Medication Hypothesis of Tobacco Smoking in Schizophrenia. Biol Psychiatry 2013.
132. Postma P, Gray JA, Sharma T, et al. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy subjects and persons with schizophrenia. Psychopharmacology 2006; 184: 589-599.
133. Sacco KA, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005; 62: 649-59.
134. Hong LE, Summerfelt A, Mitchell BD, et al. Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch Gen Psychiatry 2008; 65: 1008-16.
135. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998; 24: 189-202.
136. Turetsky BI, Dent G, Jaeger J, Zukin SR. P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients. Psychopharmacology (Berl) 2012; 221: 39-52.
137. Adler LE, Olincy A, Cawthra EM, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 2004; 161: 1822-8.
138. Su L, Cai Y, Wang L, Shi S. Various effects of antipsychotics on P50 sensory gating in Chinese schizophrenia patients: a meta-analysis. Psychiatr Danub 2012; 24: 44-50.
139. Nagamoto HT, Adler LE, McRae KA, et al. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Neuropsychobiology 1999; 39: 10-7.
140. Becker J, Gomes I, Ghisolfi ES, et al. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin Neurophysiol 2004; 115: 396-401.
141. Brinkmeyer J, Mobascher A, Musso F, et al. P50 sensory gating and smoking in the general population. Addict Biol 2011; 16: 485-98.
142. Crawford HJ, McClain-Furmanski D, Castagnoli N, Jr., Castagnoli K. Enhancement of auditory sensory gating and stimulus-bound gamma band (40 Hz) oscillations in heavy tobacco smokers. Neurosci Lett 2002; 317: 151-5.
143. Croft RJ, Dimoska A, Gonsalvez CJ, Clarke AR. Suppression of P50 evoked potential component, schizotypal beliefs and smoking. Psychiatry Res 2004; 128: 53-62.
144. Wan L, Crawford HJ, Boutros N. P50 sensory gating: impact of high vs. low schizotypal personality and smoking status. Int J Psychophysiol 2006; 60: 1-9.
145. Knott V, de la Salle S, Smith D, et al. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors. J Psychopharmacol 2013.
146. Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord 2002; 1: 149-62.
147. Winterer G, Gallinat J, Brinkmeyer J, et al. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 2013; 64: 197-204.
148. Zhang XY, Liu L, Liu S, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry 2012; 169: 974-81.
149. Inami R, Kirino E, Inoue R, Arai H. Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol Biochem Behav 2005; 80: 453-61.
150. Harkrider AW, Hedrick MS. Acute effect of nicotine on auditory gating in smokers and non-smokers. Hear Res 2005; 202: 114-28.
151. Baldeweg T, Wong D, Stephan KE. Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials. Int J Psychophysiol 2006; 59: 49-58.
152. Martin LF, Davalos DB, Kisley MA. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tob Res 2009; 11: 698-706.
153. Dunbar G, Boeijinga PH, Demazieres A, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007; 191: 919-29.
154. Fisher DJ, Grant B, Smith DM, Borracci G, Labelle A, Knott VJ. Nicotine and the hallucinating brain: Effects on mismatch negativity (MMN) in schizophrenia. Psychiatry Research 2012; 196: 181-187.
155. Hirayasu Y, Potts GF, Kwon JS, et al. Auditory mismatch negativity in schizophrenia: topographic evaluation with a high-density recording montage. American Journal of Psychiatry 1998; 155: 1281-1284.
156. Youn T, Park H-J, Kim J-J, Kim MS, Kwon JS. Altered hemispheric asymmetry and positive symptoms in schizophrenia: equivalent current dipole of auditory mismatch negativity. Schizophrenia research 2003; 59: 253-260.
157. Fisher DJ, Grant B, Smith DM, Borracci G, Labelle A, Knott VJ. Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified 'optimal' multi-feature paradigm. International Journal of Psychophysiology 2011; 81: 245-251.
158. Houlihan ME, Pritchard WS, Robinson JH. Effects of smoking/nicotine on performance and event-related potentials during a short-term memory scanning task. Psychopharmacology (Berl) 2001; 156: 388-96.
159. Knott V, Bosman M, Mahoney C, Ilivitsky V, Quirt K. Trans-dermal nicotine: single dose effects on mood, EEG, performance, and event-related potentials. Pharmacol Biochem Behav 1999; 63: 253-61.
160. Kodama E, Morita K, Kinoshita S, Miyahira A, Nakamura J, Maeda H. Inhibitory effect of smoking on event-related potentials in schizophrenic patients: Comparison with healthy subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1998; 22: 1275-1288.
161. Edwards JA, Wesnes K, Warburton DM, Gale A. Evidence of more rapid stimulus evaluation following cigarette smoking. Addict Behav 1985; 10: 113-26.
162. Houlihan ME, Pritchard WS, Robinson JH. Faster P300 latency after smoking in visual but not auditory oddball tasks. Psychopharmacology (Berl) 1996; 123: 231-8.
163. Michel C, Hasenfratz M, Nil R, Battig K. Cardiovascular, electrocortical, and behavioral effects of nicotine chewing gum. Klin Wochenschr 1988; 66 Suppl 11: 72-9.
164. Lindgren M, Stenberg G, Rosen I. Effects of nicotine in a bimodal attention task. Neuropsychobiology 1998; 38: 42-9.
165. Lindgren M, Molander L, Verbaan C, Lunell E, Rosen I. Electroencephalographic effects of intravenous nicotine--a dose-response study. Psychopharmacology (Berl) 1999; 145: 342-50.
166. Knott V, McIntosh J, Millar A, et al. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist. Pharmacol Biochem Behav 2006; 85: 228-42.
167. Anokhin AP, Vedeniapin AB, Sirevaag EJ, et al. The P300 brain potential is reduced in smokers. Psychopharmacology (Berl) 2000; 149: 409-13.
168. Neuhaus A, Bajbouj M, Kienast T, et al. Persistent dysfunctional frontal lobe activation in former smokers. Psychopharmacology (Berl) 2006; 186: 191-200.
169. Ascioglu M, Dolu N, Golgeli A, Suer C, Ozesmi C. Effects of cigarette smoking on cognitive processing. Int J Neurosci 2004; 114: 381-90.
170. Evans DE, Maxfield ND, Van Rensburg KJ, Oliver JA, Jentink KG, Drobes DJ. Nicotine Deprivation Influences P300 Markers of Cognitive Control. Neuropsychopharmacology 2013.
171. Mobascher A, Warbrick T, Brinkmeyer J, et al. Nicotine effects on anterior cingulate cortex in schizophrenia and healthy smokers as revealed by EEG-informed fMRI. Psychiatry Research: Neuroimaging 2012; 204: 168-177.
172. Tregellas JR, Tanabe JL, Martin LF, Freedman R. fMRI of response to nicotine during a smooth pursuit eye movement task in schizophrenia. American Journal of Psychiatry 2005; 162: 391-393.
173. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 1997; 154: 805-11.
174. Krystal JH, D'Souza DC, Karper LP, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999; 145: 193-204.
175. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6: 869-72.
176. Lambe EK, Picciotto MR, Aghajanian GK. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 2003; 28: 216-25.
177. D'Souza DC, Ahn K, Bhakta S, et al. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry 2012; 72: 785-94.
178. Rowland LM, Beason-Held L, Tamminga CA, Holcomb HH. The interactive effects of ketamine and nicotine on human cerebral blood flow. Psychopharmacology (Berl) 2010; 208: 575-84.
179. Knott VJ, Millar AM, McIntosh JF, et al. Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention. Biol Psychol 2011; 88: 83-93.
180. Jackson A, Nesic J, Groombridge C, Clowry O, Rusted J, Duka T. Differential involvement of glutamatergic mechanisms in the cognitive and subjective effects of smoking. Neuropsycho-pharmacology 2009; 34: 257-65.
181. Stryjer R, Strous RD, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol 2003; 26: 12-7.
182. Buchanan RW, Summerfelt A, Tek C, Gold J. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 2003; 59: 29-33.
183. Mendelsohn E, Rosenthal M, Bohiri Y, Werber E, Kotler M, Strous RD. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int Clin Psychopharmacol 2004; 19: 319-24.
184. Lenzi A, Maltinti E, Poggi E, Fabrizio L, Coli E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol 2003; 26: 317-21.
185. Bora E, Veznedaroglu B, Kayahan B. The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 2005; 28: 139-41.
186. Risch SC, McGurk S, Horner MD, et al. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase 2001; 7: 105-10.
187. Tugal O, Yazici KM, Anil Yagcioglu AE, Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol 2004; 7: 117-23.
188. Erickson SK, Schwarzkopf SB, Palumbo D, Badgley-Fleeman J, Smirnow AM, Light GA. Efficacy and tolerability of low-dose donepezil in schizophrenia. Clin Neuropharmacol 2005; 28: 179-84.
189. Nahas Z, George MS, Horner MD, et al. Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase 2003; 9: 274-82.
190. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002; 51: 349-57.
191. Lee BJ, Lee JG, Kim YH. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol 2007; 21: 421-7.
192. Lee SW, Lee JG, Lee BJ, Kim YH. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol 2007; 22: 63-8.
193. Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005; 181: 358-63.
194. Mazeh D, Zemishlani H, Barak Y, Mirecki I, Paleacu D. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. Int Psychogeriatr 2006; 18: 429-36.
195. Kohler CG, Martin EA, Kujawski E, Bilker W, Gur RE, Gur RC. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2007; 12: 412-21.
196. Fagerlund B, Soholm B, Fink-Jensen A, Lublin H, Glenthoj BY. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol 2007; 30: 3-12.
197. Akhondzadeh S, Gerami M, Noroozian M, et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1810-5.
198. Keefe RS, Malhotra AK, Meltzer HY, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsycho-pharmacology 2008; 33: 1217-28.
199. Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull 2003; 29: 45-55.
200. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsycho-pharmacology 2006; 31: 2033-46.
201. Aasen I, Kumari V, Sharma T. Effects of rivastigmine on sustained attention in schizophrenia: an FMRI study. J Clin Psychopharmacol 2005; 25: 311-7.
202. Kumari V, Aasen I, ffytche D, Williams SC, Sharma T. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage 2006; 29: 545-56.
203. Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006; 85: 73-83.
204. Chouinard S, Stip E, Poulin J, et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin 2007; 23: 575-83.
205. Guillem F, Chouinard S, Poulin J, et al. Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 934-45.
206. Lopes C, Pereira EF, Wu HQ, et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther 2007; 322: 48-58.
207. Schilstrom B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsycho-pharmacology 2007; 32: 43-53.
208. Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003; 305: 1024-36.
209. Dajas-Bailador FA, Heimala K, Wonnacott S. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release. Mol Pharmacol 2003; 64: 1217-26.
210. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 2006; 60: 530-3.
211. Dyer MA, Freudenreich O, Culhane MA, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008; 102: 88-95.
212. Sacco KA, Creeden C, Reutenauer EL, George TP. Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophr Res 2008; 103: 326-7.
213. Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry 2007; 68: 410-5.
214. Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res 2011; 125: 267-77.
215. Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008; 165: 82-9.
216. Singh J, Kour K, Jayaram MB. Acetylcholinesterase inhibitors for schizophrenia. Cochrane Database Syst Rev 2012; 1: CD007967.
217. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol 2006; 70: 801-5.
218. Fiore M. Treating tobacco use and dependence: 2008 update: Clinical practice guideline. DIANE Publishing 2008.
219. Ahmed AI, Ali AN, Kramers C, Harmark LV, Burger DM, Verhoeven WM. Neuropsychiatric adverse events of varenicline: a systematic review of published reports. J Clin Psychopharmacol 2013; 33: 55-62.
220. Shim JC, Jung DU, Jung SS, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012; 37: 660-8.
221. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 110: 149-55.
222. Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011; 68: 1195-206.
223. Waldo MC, Woodward L, Adler LE. Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study. Psychiatry Res 2010; 175: 179-80.
224. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology (Berl) 2012; 219: 25-34.
225. Velligan D, Brenner R, Sicuro F, et al. Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia. Schizophr Res 2012; 134: 59-64.
226. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-8.
227. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-7.
228. Tregellas JR, Olincy A, Johnson L, et al. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 2010; 35: 938-42.
229. Tregellas JR, Tanabe J, Rojas DC, et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2011; 69: 7-11.
230. Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 2010; 9: 27.
231. Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsycho-pharmacology 2013; 38: 968-75.
232. Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73: 654-60.
233. Ozbilen M, Adams CE, Marley J. Anticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium- and long-term: systematic review and meta-analysis. Curr Med Chem 2012; 19: 5214-8.
234. Stormer VS, Passow S, Biesenack J, Li SC. Dopaminergic and cholinergic modulations of visual-spatial attention and working memory: insights from molecular genetic research and implications for adult cognitive development. Dev Psychol 2012; 48: 875-89.